Difference between revisions of "Sutimlimab (Enjaymo)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 9: | Line 9: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2022-11-15: Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with [[Cold agglutinin disease|cold agglutinin disease (CAD)]]. | *2022-11-15: Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with [[Cold agglutinin disease|cold agglutinin disease (CAD)]]. | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2022-06-20: A drug with a new active ingredient indicated for the treatment of [[cold agglutinin disease]]. | ||
| + | |||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' BIVV-009 |
*'''Generic name:''' sutimlimab-jome | *'''Generic name:''' sutimlimab-jome | ||
*'''Brand name:''' Enjaymo | *'''Brand name:''' Enjaymo | ||
| Line 22: | Line 25: | ||
[[Category:EMA approved in 2022]] | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] | ||
| + | [[Category:PMDA approved in 2022]] | ||
Latest revision as of 12:09, 19 August 2023
Mechanism of action
Anti-C1s antibody
Diseases for which it is used
History of changes in FDA indication
- 2022-02-04: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)
History of changes in EMA indication
- 2022-11-15: Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
History of changes in PMDA indication
- 2022-06-20: A drug with a new active ingredient indicated for the treatment of cold agglutinin disease.
Also known as
- Code name: BIVV-009
- Generic name: sutimlimab-jome
- Brand name: Enjaymo